Leju Finance Li Li
On June 28, Cali Biotechnology Co., Ltd. (hereinafter referred to as “Cali Biotech” or “Callie Biotech”) once again submitted listing application materials on the Hong Kong Stock Exchange. According to information, Callie Biotech submitted a statement on the Hong Kong Stock Exchange on January 31, 2022.
Jiali Biotech is a biotechnology company. The company's main entity in China is Jiali (Shenzhen) Biotechnology Co., Ltd., founded in October 2019. Former names include Shenzhen Shenhua Biotechnology Co., Ltd., and Xuanbang (Shenzhen) Biotechnology Co., Ltd.
According to the prospectus, Gary Biotech was founded in 2016 and is committed to developing new drugs for the perioperative period based on drug delivery platforms and other patented technology, with a view to expanding the company's coverage to the production and commercialization of pharmaceutical products developed for it to achieve end-to-end development capabilities.
According to reports, Gary Biotech's product line focuses on non-opioid post-operative pain management, anti-inflammatory pain control, anesthesia, and sedation, given unmet medical needs. Currently, the company has a total of three drug candidates. No products have been approved for commercial sale, nor have they generated any revenue through product sales.
Gary Biotech stated in its prospectus that the company's operations focus on raising capital, establishing an intellectual property portfolio, drug discovery, and conducting pre-clinical research and clinical trials of drug candidates. According to data from Wisdom Bud, Gary Biotech has a total of 2 patents worldwide, all in the US, and they are all related to “topical anesthetic lotion.” The application period is 2021.
In 2021-2022, Caltech recorded net losses of $112 million and $91.888 million respectively, mainly due to R&D costs and administrative expenses. During the reporting period, Callie Biotech's R&D expenses were RMB 62.85.7 million and RMB 84.204 million respectively, while administrative expenses were RMB 30.71 million and RMB 11.819 million respectively.
Behind Lin Dibang, the actual controller of Cali Biotech, is Lin Li, once known as “the richest man in Shenzhen.” According to the prospectus, Cali Biotech's legal representative, executive director, chairman and chief financial officer Lin Dibang controls 58.80% of the company's shares through Cali Nova.
According to public information, Lin Li was ranked 41st in China's 100 richest people with a net worth of 14 billion yuan in 2007, becoming the richest person in Shenzhen. In 2021, Lin Li's total wealth reached 81 billion yuan, ranking 61st in Hurun's 100 richest list.